FOSAPREPITANT JUNO fosaprepitant (as dimeglumine) 150 mg powder for injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

fosaprepitant dimeglumine, Quantity: 245.3 mg (Equivalent: fosaprepitant, Qty 150 mg)

Verfügbar ab:

Juno Pharmaceuticals Pty Ltd

Darreichungsform:

Injection, powder for

Zusammensetzung:

Excipient Ingredients: lactose monohydrate; dilute hydrochloric acid; polysorbate 80; disodium edetate; sodium hydroxide

Verabreichungsweg:

Intravenous

Einheiten im Paket:

1 vial

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

FOSAPREPITANT JUNO, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration),? moderately emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration).

Produktbesonderheiten:

Visual Identification: A white or off-white block-shaped solid or powder in a glass vial with a rubber stopper and an aluminium seal with with a plastic flip off top.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Berechtigungsstatus:

Registered